Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFM-EPO-PRETAR
2024-515356-21-00Phase 3Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of epoetin alfa in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Time to RBC transfusion dependence. Started Sep 2024; status: completed.
02
Drugs
epoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2024-515356-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515356-21-00.